Singapore, July 10 -- Leading GMP cell CDMO I Peace, Inc., specialising in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, has agreed with Vita Therapeutics (Vita) to jointly develop universal iPS cells that will be used for cell transplantation therapy.

GMP-grade iPS cells will be modified with proprietary, licensed gene editing technology to make a base platform hypoimmune line where Class I and II HLA genes that determine rejection have been depleted. These hypoimmune lines can be further customised in I Peace cGMP facilities.

I Peace will provide its GMP iPS cell-related technology to generate the master cell bank (MCB) for the parent line and the modified subclones, while Vita will provide the technology nec...